This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center Identifier:
First received: April 18, 2007
Last updated: November 24, 2015
Last verified: November 2015

RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

PURPOSE: This phase II trial is studying how well sunitinib works in treating patients with brain metastases caused by kidney cancer or melanoma.

Condition Intervention Phase
Kidney Cancer Melanoma (Skin) Metastatic Cancer Drug: sunitinib malate Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study of SU11248 (Sunitinib) in Patients With Renal Cell Carcinoma and Melanoma Metastatic to the Brain

Resource links provided by NLM:

Further study details as provided by Memorial Sloan Kettering Cancer Center:

Primary Outcome Measures:
  • Central Nervous System (CNS) Response Rate by RECIST Criteria [ Time Frame: up to a year ]
    Response and progression will be evaluated in this study using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee. Changes in only the largest diameter (unidimensional measurement) of the tumor lesions are used in RECIST. Measurable lesions are defined as those that can be accurately measured in at least one dimension (longest diameter to be recorded) as >20 mm with conventional techniques (CT, MRI, X-ray) or as >10 mm with spiral CT scan. This study will use a minimum diameter of 10 mm for measurable lesions in the brain, regardless of imaging modality. All tumor measurements must be recorded in millimeters (or decimal fractions of centimeters). All other lesions are considered non-measurable disease. Bone lesions, leptomeningeal disease, ascites, pleural/pericardial effusions, inflammatory breast disease, and cystic lesions are all nonmeasurable.

Enrollment: 8
Study Start Date: March 2007
Study Completion Date: August 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Sunitinib
Patients will be treated with 50 mg daily for four out of every six weeks.
Drug: sunitinib malate

Detailed Description:



  • Determine the efficacy of sunitinib malate, in terms of objective radiographic response of brain lesions, in patients with brain metastases secondary to renal cell carcinoma or melanoma.


  • Determine overall and progression-free survival.

OUTLINE: Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every 6 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.

After completion of study therapy, patients are followed periodically.


Ages Eligible for Study:   18 Years to 120 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed melanoma or renal cell carcinoma

    • Metastatic brain disease
  • Must have assessable target intracranial lesion(s), defined as measurable disease ≥ 10 mm in longest diameter that is not appropriate for stereotactic radiosurgery or surgical resection

    • Lesions previously treated with radiosurgery AND not eligible for resection can only be used as target lesions if there has been true tumor progression on baseline scan (i.e., ≥ 20% increase in longest diameter of lesion) rather than radionecrosis

      • True progression must be confirmed by PET scan or other corroborating imaging used to distinguish radionecrosis
  • No leptomeningeal metastases or primary dural metastases


  • ECOG performance status (PS) 0-1 OR Karnofsky PS 60-100%
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Total leukocyte count ≥ 3,000/mm³
  • ANC ≥ 1,500/mm³
  • Platelet count ≥ 100,000/mm³
  • Creatinine ≤ 2.0 times upper limit of normal (ULN)
  • Bilirubin ≤ 1.5 times ULN
  • Hemoglobin ≥ 9.0 g/dL
  • Calcium ≤ 12.0 mg/dL
  • AST and ALT ≤ 1.5 times ULN
  • PT ≤ 1.5 times ULN
  • No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
  • No uncontrolled medical illness including, but not limited to, any of the following:

    • Hypertension (i.e., blood pressure > 150/100 mm Hg)
    • Thyroid disease
    • Severe valvular disease
    • Severe pulmonary disease
    • HIV/AIDS
    • Severe psychiatric illness
  • No cardiac dysrhythmia ≥ grade 2
  • No prolonged QTc interval on baseline EKG
  • No systemic hemorrhage ≥ grade 2 within the past 4 weeks

    • No CNS hemorrhage ≥ grade 2

      • Grade 1 (asymptomatic) CNS hemorrhage allowed at investigator's discretion
  • None of the following within the past 6 months:

    • Myocardial infarction
    • Unstable angina
    • Symptomatic congestive heart failure
    • Stroke/transient ischemic attack
    • Pulmonary embolism
  • Ejection fraction ≥ 50% by baseline echocardiogram OR < 20% decrease in ejection fraction from a prior study


  • No prior multi-targeted tyrosine kinase inhibitor therapy (e.g., sunitinib malate or sorafenib)
  • No coronary/peripheral arterial bypass surgery within the past 6 months
  • More than 4 weeks since prior surgery and recovered
  • More than 4 weeks since prior and no other concurrent experimental therapy or cytotoxic chemotherapy
  • More than 4 weeks since prior immunotherapy
  • More than 2 weeks since prior stereotactic radiosurgery and recovered
  • More than 7 days since prior and no concurrent drugs that interact with CYP3A4 family, including enzyme-inducing antiepileptic drugs, warfarin, or Hypericum perforatum extract (St. John's wort)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00462982

United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10021
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Principal Investigator: Lauren E. Abrey, MD Memorial Sloan Kettering Cancer Center
Principal Investigator: Paul B. Chapman, MD Memorial Sloan Kettering Cancer Center
Principal Investigator: Robert J. Motzer, MD Memorial Sloan Kettering Cancer Center
  More Information

Responsible Party: Memorial Sloan Kettering Cancer Center Identifier: NCT00462982     History of Changes
Other Study ID Numbers: 07-009
P30CA008748 ( US NIH Grant/Contract Award Number )
Study First Received: April 18, 2007
Results First Received: October 21, 2015
Last Updated: November 24, 2015

Keywords provided by Memorial Sloan Kettering Cancer Center:
stage IV melanoma
tumors metastatic to brain
stage IV renal cell cancer
recurrent melanoma
recurrent renal cell cancer

Additional relevant MeSH terms:
Neoplasm Metastasis
Kidney Neoplasms
Carcinoma, Renal Cell
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Neoplastic Processes
Pathologic Processes
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Neoplasms, Glandular and Epithelial
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors processed this record on June 22, 2017